ArticleClinical rheumatology2018
Psoriatic disease treatment nowadays: unmet needs among the "jungle of biologic drugs and small molecules".
Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- First-in-Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants.Clinical pharmacology and therapeutics · 2025Trial
- Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.Advances in rheumatology (London, England) · 2024Article
- Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study.Clinical, cosmetic and investigational dermatology · 2023Article
- Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis.Frontiers in medicine · 2023Article
- Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab.Dermatologic therapy · 2022Article
- Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study.Dermatologic therapy · 2022Article
- Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection.Clinical drug investigation · 2022Article
- Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge.Psoriasis (Auckland, N.Z.) · 2022Review
- Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study.Dermatologic therapy · 2022Article
- Brodalumab Is Associated with High Rates of Complete Clearance and Quality of Life Improvement: A Subgroup Analysis of Patients with Psoriasis and Concomitant Psoriatic Arthritis.Dermatology (Basel, Switzerland) · 2022Article
- Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting.Clinical rheumatology · 2020Article
- Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.Journal of experimental pharmacology · 2020Review
- Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative.Rheumatology advances in practice · 2020Review
- Late-Onset and Elderly Psoriatic Arthritis: Clinical Aspects and Management.Drugs & aging · 2019Review
- Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date.Clinical, cosmetic and investigational dermatology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29644570What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.